Answer
It treats selected adults with AChR-antibody-positive generalised myasthenia gravis alongside standard therapy. The subcutaneous formulation is also licensed for selected adults with active CIDP after previous corticosteroid or immunoglobulin treatment.
Sources for this answer
- Vyvgart 1000 mg solution for injection in pre-filled syringe — Current selected SmPCemc · Summary of Product Characteristics
- Vyvgart 20 mg/mL concentrate for solution for infusion — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.